Reflections on an excellent EBMT 2018

Reflections on an excellent EBMT 2018

VJHemOnc

1 year
30 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, proved to be an exciting congress with >5,000 delegates in attendance - the highest attendance to date. Here, Tony Pagliuca, MBBS, MA, FRCP, FRCPath, from Kings College Hospital NHS Foundation Trust, London, UK, highlights the importance of bringing together healthcare professionals with patients during meetings such as EBMT. Prof. Pagliuca outlines his meeting highlights, including transplantation in myelodysplastic syndrome and while utilizing CAR T-cell therapy. Several sessions focused on CAR T-cell therapy for a range of malignancies, including the presentation of data from the CALM first-in-human trial (NCT02746952) in adult patients with relapsed B-cell acute lymphoblastic leukemia, showing improved outcomes in patients previously unresponsive to treatment.
Up Next Autoplay
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Human Immune Monitoring Center in Mount Sinai to Analyze the Efficacy of a New Drug for Cancer Therapy
Category: General
2 Views
Mount Sinai Health System 1 week
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019
Category: General
20 Views
Cancer-News 1 month
Interesting Data Presented at WCLC 2019
Interesting Data Presented at WCLC 2019
Category: General
13 Views
Cancer-News 1 month
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
Category: General
18 Views
Cancer-News 1 month
The iQ Group Global acquires new anticancer drug platform from University of Texas
The iQ Group Global acquires new anticancer drug platform from University of Texas
Category: General
12 Views
Cancer-News 1 month
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Clinical insights for hematological malignancies from an artificial intelligence decision-support tool.
Category: General
118 Views
Annual-Meeting 5 months
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Grandma Shout-Out: Very Grateful For Everything...Maybe Not All The Cooking
Category: General
26 Views
Annual-Meeting 5 months
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Questions About Larotrectinib: Who Should Be Tested, How Long Should They Be Treated, What Agent To Use
Category: General
48 Views
Annual-Meeting 5 months
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Larotrectinib Efficacy & Safety In Pediatric TRK Fusion Cancer Patients: 94% Of The Children Treated With Larotrectinib Achieved A Response
Category: General
76 Views
Annual-Meeting 5 months
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
How To Identify Patients With An NTRK Gene Fusion: Will Require A Very Broad Genomic Sequencing
Category: General
301 Views
Annual-Meeting 5 months